多西紫杉醇
医学
内科学
乳腺癌
肿瘤科
化疗
毒性
不利影响
癌症
阶段(地层学)
病态的
临床研究阶段
胃肠病学
生物
古生物学
作者
Laura G. Estévez,J. Cuevas,Antonio Antón,Jesús Florián,José Manuel López‐Vega,A. Velasco,Francisco Lobo,Ana Herrero,José Fortes
出处
期刊:PubMed
日期:2003-02-01
卷期号:9 (2): 686-92
被引量:20
摘要
This is one of the first reports of weekly docetaxel (Taxotere) in the neoadjuvant treatment of stage II and III breast cancer. We evaluated docetaxel's efficacy and safety and analyzed correlations between response and the expression of c-erbB2, ER status, and Ki-67 labeling index.Patients with previously untreated, stage II and III breast cancer were entered into the study. Docetaxel (40 mg/m(2)) was given i.v. once weekly for the first 6 weeks of an 8-week cycle for 2 cycles.A total of 56 patients were evaluated by intention-to-treat analysis for efficacy and safety. The overall clinical response rate was 68% (complete and partial response, 29 and 39%, respectively). Nine patients (16%) achieved a pathological complete response. There was no correlation between response to docetaxel and the expression of molecular markers, however, the majority of the pathological complete responses were observed in patients with c-erbB2-negative tumors. Nonhematological toxicity was more common than hematological toxicity, with alopecia and asthenia the most frequently reported adverse events (89 and 77% of patients, respectively). Severe hematological toxicity was rare.Weekly docetaxel appears to be very effective in the neoadjuvant setting. A high pathological response rate was achieved with tolerable toxicity.
科研通智能强力驱动
Strongly Powered by AbleSci AI